Eosinophilic Esophagitis Clinical Trial
Official title:
Prospective Pilot Study Evaluating the Efficacy of Low-Dose Topical Steroids in Maintaining Histologic Remission of Eosinophilic Esophagitis in Children
This study evaluates the decrease in steroid dosing for patients who have achieved remission on a full dose of steroids. Once a patient is in remission they will be enrolled in this study if they choose to decrease the steroid dosing.
As the disease usually recurs once steroids are discontinued, and there is concern for complications of untreated disease, continuation of steroids is indefinite after induction of remission. The short-term safety of topical steroids has been well established; however, long-term safety has not been studied in EoE. Concerns for long-term complications of chronic steroid therapy include effects on bone density and stature as has been suggested by literature in patients with asthma treated with inhaled corticosteroids chronically.4, 5 It remains unclear whether symptom and histologic remission, once achieved, can be maintained with a lower, to be defined, dosage of topical steroids.6 This is critical to prevent the major complications associated with uncontrolled eosinophilic inflammation: fibrotic remodeling (scarring) of the esophagus and eventual stricture (narrowing of the esophagus).7-11 Several studies have demonstrated that remission with induction (approximately 3 months of therapy) dose topical steroids resulted in resolution of inflammation and concurrent reversal of sub-epithelial early-stage fibrosis.12-18 It has not, however, been established whether fibrosis recurs when patients are maintained on induction doses long-term or whether lower "maintenance" dosing is sufficient. Studies are therefore needed to demonstrate whether fibrosis can be prevented from recurring long-term, ideally at a lower maintenance dose to minimize potential complications of therapy. Therapeutic strategies that achieve continuous and sustained remission with resolution of eosinophilic inflammation will prevent chronic symptoms along with remodeling, fibrosis and eventual esophageal stricture. The rationale for utilizing lower dose topical steroids for maintaining clinical and histologic remission in children is the potential to lower the steroid-related side effects including contracting oral and/or esophageal fungal infections (a yeast infection which causes white patches in the mouth and throat), loss of bone density, suppression of adrenal-cortical axis (turns off the body's usual production of cortisol, which helps the body maintain a balance and respond to stress), and failure to achieve linear growth (height) potential. There are no studies that have properly quantified the risk of swallowed steroids in EoE, thus the investigators are presuming and postulating a lower cumulative risk of adverse effects from long-term use of the medication with this lower dose than the standard dose. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03382678 -
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
|
||
Completed |
NCT05083312 -
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
|
Phase 3 | |
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT03633617 -
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
Terminated |
NCT04543409 -
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
|
Phase 3 | |
Completed |
NCT04941742 -
The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)
|
||
Terminated |
NCT02314455 -
Esophageal Absorption in EoE
|
N/A | |
Completed |
NCT01953575 -
Mucosal Impedance and Eosinophilic Esophagitis
|
N/A | |
Completed |
NCT01386112 -
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04991935 -
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
|
Phase 3 | |
Not yet recruiting |
NCT05896891 -
San Raffaele EoE Biobank
|
||
Active, not recruiting |
NCT05482256 -
A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis
|
N/A | |
Recruiting |
NCT05485155 -
Zemaira Eosinophilic Esophagitis Pilot Study
|
Phase 2 | |
Recruiting |
NCT04149470 -
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
|
Phase 4 | |
Recruiting |
NCT04416217 -
Eosinophilic Esophagitis Steroid Safety Study
|
||
Completed |
NCT05084963 -
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Recruiting |
NCT02331849 -
Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.
|
N/A | |
Active, not recruiting |
NCT02202590 -
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
|
N/A | |
Active, not recruiting |
NCT05176249 -
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
|